Fluconazole: Physicochemical Properties, Mechanism of Action, and Key Points for Clinical and Research Applications

Fluconazole is a triazole antifungal agent (commonly categorized within the azole antifungal class) with the molecular formula C13H12F2N6O, molecular weight 306.271, and CAS No. 86386-73-4. It is a white to off-white crystalline powder that is poorly soluble in water but readily soluble in glacial acetic acid, methanol, or ethanol. Fluconazole inhibits fungal cytochrome P450-associated pathways, thereby blocking ergosterol biosynthesis and disrupting fungal cell membrane structure and function. It has important therapeutic value against deep fungal infections caused by Candida spp. and Cryptococcus spp. Fluconazole is well absorbed after oral administration, has high bioavailability, low plasma protein binding, and is primarily excreted unchanged via the kidneys. Its clinically meaningful distribution into body fluids, including cerebrospinal fluid (CSF), underpins its established role in the treatment and maintenance strategies for central nervous system (CNS) fungal infections such as cryptococcal meningitis.

Keywords: fluconazole; triazole; ergosterol; CYP51; Candida; Cryptococcus; pharmacokinetics; resistance; PK/PD

I. Compound and Formulation Fundamentals

1.1 Basic information and physicochemical properties

(1) Basic information

① Molecular formula: C13H12F2N6O.

② Molecular weight: 306.271.

③ CAS No.: 86386-73-4.

(2) Physicochemical properties

① Appearance: white to off-white crystalline powder.

② Solubility: poorly soluble in water; readily soluble in glacial acetic acid, methanol, or ethanol.

③ Melting point: approximately 138–140°C (minor variation may be observed across pharmacopeias or analytical conditions).

(3) Practical implications of physicochemical properties

① Limited aqueous solubility places emphasis on solvent systems, pH control, and salt-compatibility stability in the formulation design of oral solid dosage forms and injectable products.

② Standardization of crystalline form control and assay methodology directly affects pharmaceutical quality consistency and lot-to-lot comparability.

1.2 Key points for pharmacopeial quality control

(1) Typical approaches for identification and assay

① HPLC is commonly used for assay and related-substances control. Detection wavelengths are often set in the UV range (e.g., near 260 nm), and retention-time agreement with a reference standard is used as one identification element.

② UV spectral features and IR spectral concordance are often used for structural confirmation.

(2) Impurities and physicochemical tests

① Related-substances limits, loss on drying, residue on ignition, and heavy metals form a conventional QC framework.

② For injectable products, solution clarity and visible/subvisible particulate risks require dedicated control.

(3) Dosage forms

① Oral solid dosage forms: tablets, capsules.

② Injectable dosage forms: injection solutions (including products formulated in sodium chloride injection and related vehicles).

II. Mechanism of Action and Antifungal Spectrum

2.1 Mechanism of action

(1) Target and pathway

① Fluconazole selectively interferes with fungal cytochrome P450-associated enzyme systems, inhibiting ergosterol biosynthesis.

② Ergosterol depletion compromises membrane fluidity, permeability, and membrane protein function, thereby inhibiting fungal growth or contributing to fungal death (the effect type depends on species, concentration, and exposure duration).

(2) Selectivity and host-context considerations

① Fluconazole shows relative selectivity toward fungal P450-dependent enzymes, reducing the likelihood of direct interference with host steroid hormone synthesis. However, drug–drug interaction risks remain important at the level of human drug-metabolizing enzymes and exposure modulation in combination therapy.

2.2 Antifungal spectrum and indication framework

(1) Major susceptible fungi and common disease spectra

① Candida infections: including oropharyngeal and esophageal candidiasis, as well as disseminated or invasive candidiasis (e.g., peritonitis, pneumonia, urinary tract infection) when susceptibility is confirmed.

② Cryptococcal infections: including cryptococcal meningitis and other cryptococcosis; in CNS disease, fluconazole is often used as part of consolidation or maintenance strategies after induction therapy, depending on guideline-directed regimens and pathogen susceptibility.

③ Other fungi: under specific conditions, fluconazole may be considered in alternative or step-down strategies for certain endemic deep mycoses, contingent on pathogen identification and standardized treatment pathways.

(2) Examples in skin and mucosal applications

① Recurrent vulvovaginal candidiasis (RVVC) may be managed using intermittent or maintenance strategies to reduce recurrence risk.

② Malassezia-associated conditions (e.g., Malassezia folliculitis) may be treated with systemic fluconazole in selected protocols; outcomes and relapse risks depend on host factors and pathogen spectrum and require follow-up evaluation.

III. Pharmacokinetics and Dosing Design

3.1 Absorption, distribution, metabolism, and excretion

(1) Absorption

① Oral absorption is good, with bioavailability reported around 90%.

② Food, antacids, or H2 receptor antagonists have relatively limited impact on oral absorption in typical settings.

(2) Distribution

① The apparent volume of distribution approximates total body water, indicating broad distribution across body fluids.

② Plasma protein binding is low (approximately 11%–12%), supporting a relatively high free-drug fraction.

③ Effective concentrations can be detected in skin, blister fluid, peritoneal fluid, sputum, and other compartments; urinary and skin concentrations may exceed plasma levels by an order of magnitude in some contexts.

④ CNS: under meningeal inflammation, CSF concentrations can reach approximately 54%–85% of plasma concentrations, providing a pharmacokinetic basis for use in cryptococcal meningitis and related CNS mycoses.

(3) Metabolism and excretion

① Hepatic metabolism contributes a relatively small fraction.

② Renal excretion predominates, with more than 80% of the administered dose excreted unchanged in urine.

③ Elimination half-life is approximately 27–37 hours and is substantially prolonged in renal impairment.

④ Hemodialysis or peritoneal dialysis can partially remove fluconazole; dosing for dialysis patients should be designed in relation to dialysis schedules and drug-clearance characteristics.

3.2 Key variables in dose selection

(1) Infection site and severity

① CNS infections and invasive deep infections typically require higher loading and maintenance strategies and emphasize sufficient treatment duration.

② Mucocutaneous infections may use lower-dose or intermittent regimens, with adjustment based on recurrence risk and microbiological evidence.

(2) Renal function

① Because renal clearance is dominant, renal impairment requires dose adjustment or interval extension based on renal-function indices.

(3) Treatment endpoints

① Therapy should continue until clinical features and laboratory/microbiological indicators support infection control or clearance, to reduce relapse risk and resistance selection pressure.

IV. Clinical Application Scenarios

4.1 Treatment and maintenance strategies for deep fungal infections

(1) Cryptococcal meningitis

① CSF distribution supports its role in post-induction maintenance or consolidation components, depending on standardized regimens.

② Maintenance emphasizes adequate duration and adherence to reduce relapse risk.

(2) Invasive candidiasis

① When the pathogen is confirmed and susceptible, fluconazole may be used as systemic therapy or within step-down strategies.

② In immunocompromised populations, course management should be strengthened and combined with source control and assessment of concomitant medications.

4.2 Mucosal and cutaneous fungal applications

(1) Oropharyngeal and esophageal candidiasis

① Often used when local therapy is insufficient or in immunocompromised settings; regimens and duration should match infection site and severity.

(2) RVVC

① Single-dose, periodic, or maintenance regimens can reduce recurrence; effectiveness depends on species distribution, resistance profile, and adherence.

(3) Malassezia-associated skin conditions

① Used in selected systemic regimens; response and recurrence depend on lesion extent, trigger control, and pathogen profile, requiring follow-up evaluation.

V. Research Applications: Pharmacodynamics, Resistance Mechanisms, and Model Systems

5.1 Research positioning and boundaries

(1) Reference comparator drug:

Fluconazole is commonly used as a triazole comparator in in vitro susceptibility comparisons, combination-therapy evaluations, and biofilm pharmacodynamics studies.

(2) Mechanistic tool compound:

As an ergosterol-pathway inhibitor, it supports closed-loop evidence chains linking pathway readouts, resistance phenotypes, and genetic/protein markers, including transporter-mediated efflux and intracellular exposure.

(3) Translational bridging:

In animal models and PK/PD frameworks, exposure–response indices (e.g., AUC/MIC) enable comparability across routes, regimens, and strain susceptibilities.

5.2 In vitro pharmacodynamics and susceptibility evaluation

(1) MIC and time–kill curves

① Standardized susceptibility methods establish MIC distributions to stratify species/strain sensitivity and guide downstream mechanistic studies.

② Time–kill or growth-inhibition kinetics clarify concentration–effect–time relationships and delineate fungistatic versus potential fungicidal boundaries under defined conditions.

(2) Biofilm pharmacodynamics

① Candida biofilms can markedly alter susceptibility; evaluate drug effects during biofilm formation and on mature biofilms separately.

② Endpoints may include biomass, metabolic activity, viable counts, and structural imaging, avoiding over-inference from a single staining-based metric.

(3) Combination therapy and sensitization strategies

① Define whether the goal is synergy, dose reduction, resistance delay, or biofilm penetration, and select appropriate interaction models (e.g., Bliss, Loewe) for interpretation.

② Record inoculum, medium composition, pH, and exposure time to reduce non-comparability driven by system differences.

5.3 Resistance mechanisms and molecular marker research

(1) Efflux pump-associated resistance

① In Candida, ABC transporters (e.g., Cdr1) can reduce intracellular exposure via drug efflux and represent a major resistance mechanism.

② Use transporter transcription/protein metrics, functional efflux assays, and intracellular accumulation measurements to close the mechanistic loop.

(2) Target and pathway remodeling

① Alterations in key nodes of ergosterol biosynthesis can shift susceptibility; integrate gene expression, enzyme activity, sterol profiling, and phenotypic resistance levels.

② LC-MS-based sterol profiling can quantify pathway blockade strength and link it to growth-inhibition phenotypes.

(3) Population heterogeneity and resistance evolution

① Under long-term or sub-inhibitory exposure, resistant subpopulations may expand; serial passaging, evolution experiments, and whole-genome or targeted sequencing can map evolutionary trajectories.

② For clinical isolates, combine clonal typing with resistance markers to avoid conflating lineage differences with a single-mechanism effect.

5.4 Animal models and translational study designs

(1) Systemic and mucosal infection models

① Systemic Candida models can evaluate tissue burden, inflammatory responses, and survival outcomes; mucosal models can evaluate local burden, pathology, and recurrence risk.

② Define immune status (immunocompetent vs immunosuppressed) and infection site because they shape PD endpoints and exposure–response relationships.

(2) CNS infection research

① CSF penetration supports studies linking CSF exposure to fungal burden and inflammation. Measure plasma and CSF concentrations in parallel to support cross-compartment interpretation.

(3) PK/PD integration and dose optimization

① Use indices such as AUC/MIC to model exposure–effect relationships for comparing regimens, routes, or combination strategies.

② In models with renal-function shifts or strong compartmental differences, incorporate clearance changes into dose normalization and interpretation.

VI. Formulation and Analytical Methods: Research Sample Management, Quantitation, and Quality Control

6.1 Selecting dosage forms and routes in research

(1) Oral solid dosage forms and dissolution variables

① High oral bioavailability supports oral dosing designs, but in animal studies, solvent system, pH, and dosing volume can affect absorption.

② For self-prepared solutions, verify solubility and stability to avoid precipitation-driven underexposure.

(2) Injectable dosing and solution stability

① Injectable systems require attention to clarity, compatibility stability, and osmolality to ensure consistent dosing and reproducibility.

(3) Exposure comparability control

① For multi-group comparisons, conduct plasma concentration monitoring or sentinel sampling to verify exposure consistency and avoid formulation-driven pseudo-efficacy differences.

6.2 Quantitation and tissue-distribution studies

(1) Plasma and tissue quantitation

① LC-MS/MS is commonly used for selective quantitation in plasma, urine, CSF, and tissue homogenates and supports exposure–effect modeling.

② Tissue distribution studies should address matrix effects and recovery; isotope-labeled internal standards, spike recovery, and dilution linearity verification are recommended.

(2) Cross-compartment interpretation

① For CNS or skin-targeted studies, measure plasma and target tissue/fluid concentrations concurrently, build tissue/plasma ratios, and assess time dependence to avoid over-inference from single time points.

6.3 Quality control and experimental comparability

(1) Drug source and purity consistency

① Record lot number, purity, and moisture content; when necessary, establish HPLC fingerprints and related-substances control to support cross-lot comparability.

(2) Solution preparation and stability

① Evaluate short- and long-term stability (temperature, light, pH) and formalize SOPs to prevent drift caused by degradation or adsorption.

(3) Reporting elements

① Specify route, dose units, dosing frequency, sampling time points, quantitative method parameters, and LOD/LOQ in the Methods section to improve reproducibility and auditability.

VII. Methodological Essentials in Research and Pharmaceutical Analysis

7.1 In vitro pharmacodynamics evaluation

(1) Susceptibility testing

① Use standardized methods to obtain MIC distributions across species and interpret results jointly with resistance mechanisms and clinically relevant exposures.

(2) Combination studies

① Define endpoints (fungistatic, fungicidal, resistance suppression, or biofilm endpoints) and control inoculum, medium, and exposure time to ensure comparability.

7.2 Quality control and assay methodology

(1) HPLC related-substances control

① Use C18 columns, fit-for-purpose mobile phases, temperature control, and UV detection to manage related-substances limits, emphasizing system suitability and sensitivity validation.

(2) Titration and spectroscopic identification

① Non-aqueous titration or potentiometric titration can be used for assay; UV and IR spectroscopy support structural identity confirmation.

(3) Injectable-product checks

① Solution clarity and impurity control are directly linked to safety and acceptability and should strictly comply with quality standards.

VIII. Aladdin-Related Products

8.1 Product Matrix for Fluconazole and Related Compounds

Catalog No.	Product Name	CAS No.	Grade and Purity	Relationship to Fluconazole
I422805	Isavuconazole	241479-67-4	10mM in DMSO	Structural analog (azole-class comparator)
F408555	Fluconazole (UK 49858)	86386-73-4	Moligand™, 10mM in DMSO	Parent compound (fluconazole)
E129360	Fluconazole	86386-73-4	Moligand™, ≥98%	Parent compound (fluconazole)
F1418503	Fluconazole-C,N	1309935-84-9		Derivative/modified related substance (structural-variant reference)
F1420575	Fluconazole-d	1124197-58-5	≥99%	Impurity control (related-substances/impurity-spectrum assignment)
F1419212	Fluconazole mesylate	159532-41-9		Salt-form related substance (salt-form reference)
D734701	1, 1'-(1, 3-phenylene)di(1H-1, 2, 4-triazole)	514222-44-7		Related-substances control (related-species spectrum assignment)
E413214	Efinaconazole	164650-44-6	≥99%	Cross-comparator (azole-class efficacy reference)
E1421233	Efinaconazole-d	--	≥99%	Labeled/isotope-related compound (quantitation/control reference)

8.2 Key Reagents Commonly Used for Mechanism Dissection, Pharmacodynamics Evaluation, and Resistance Studies of Fluconazole

Category	Reagent Name	CAS No.	Workflow Step	Role in the System	Use Notes
Mechanism/sterol-pathway control	Ergosterol	57-87-4	Mechanism validation / sterol profiling	Key fungal membrane sterol; supports “ergosterol depletion” effects and sterol-profile endpoints	Keep cold and protected from light; match extraction and analytical solvent systems
Mechanism/pathway node	Lanosterol	79-63-0	Pathway readout / sterol profiling	Upstream sterol node relative to CYP51; supports profiling shifts under 14α-demethylase blockade	Build calibration curves and recovery checks aligned with LC/GC methods
Membrane readout control drug	Amphotericin B	1397-89-3	Comparator drug / mechanism separation	Sterol-binding membrane-disruptor, serving as contrast control versus azole “biosynthesis blockade”	Watch solubility and adsorption; include solvent/carrier controls
Combination/cell-wall axis control	Micafungin	235114-32-6	Combination studies / resistance stratification	Echinocandin comparator to contrast drug axes and stratify strain sensitivity	Control lot activity and storage; include bridging controls
Combination/cell-wall axis control	Anidulafungin	166663-25-8	Combination studies / susceptibility control	Echinocandin comparator for “membrane sterol axis vs cell-wall axis” reference systems	Standardize solvent fractions; avoid solvent-driven pseudo-inhibition
Nucleic-acid axis control	Flucytosine	2022-85-7	Combination / fungicidal enhancement	Nucleic-acid synthesis axis comparator often used with polyenes or azoles	Sensitivity varies by species; stratify strains
Azole-class comparator	Itraconazole	84625-61-6	Comparator / cross-resistance	Azole comparator with distinct physicochemistry and exposure behavior for within-class comparison	Highly hydrophobic; rigorously control solvent systems and effective concentration calculations
Azole-class comparator	Voriconazole	137234-62-9	Comparator / spectrum and resistance profiling	Commonly compared with fluconazole for susceptibility/resistance spectra (especially Candida spp.)	Light/temperature sensitive; prepare fresh and protect from light
Azole-class comparator	Posaconazole	171228-49-2	Comparator / high-potency azole reference	Potent triazole comparator for potency and resistance-barrier comparisons	Manage solubility and adsorption losses; consider verifying actual concentrations
Other-pathway comparator	Terbinafine	91161-71-6	Mechanism separation / combination	Squalene epoxidase inhibitor serving as an upstream sterol-pathway comparator	In combinations, design concentration and readout time windows carefully
Efflux function readout	Rhodamine 6G	989-38-8	Resistance mechanism / efflux pumps	Functional probe for efflux activity and intracellular accumulation changes	Include energy-inhibition/temperature controls to avoid miscalls
Efflux/membrane hydrophobic probe	Nile Red	7385-67-3	Resistance mechanism / membrane and efflux	Reports hydrophobic-environment distribution and efflux-associated changes to link to resistance phenotypes	Susceptible to autofluorescence; strict blank subtraction required
Biofilm endpoint (metabolic activity)	XTT	111072-31-2	Biofilm pharmacodynamics	Metabolic activity readout for evaluating drug effects on biofilms	Standardize incubation window; strongly dependent on inoculum and state
Biofilm electron-coupling aid	Menadione	58-27-5	Biofilm pharmacodynamics	Electron-coupling reagent for stabilizing XTT signals	Overdose causes toxicity/bias; optimize system first
Biofilm/staining endpoint	Crystal Violet	548-62-9	Biofilm biomass	Rapid readout of total biofilm biomass for screening and cross-comparisons	Highly sensitive to washing intensity; standardize wash steps
Common solvent/dosing vehicle	DMSO	67-68-5	Solubilization/dosing	Solubilizes hydrophobic drugs and controls dosing consistency	Fix final concentration; solvent controls are mandatory
Buffer-system component	MOPS	1132-61-2	Susceptibility/in vitro evaluation	Stabilizes pH to reduce drift in susceptibility and kinetic readouts	Fix pH and ionic strength; prioritize within- and between-batch consistency

Fluconazole, as a triazole antifungal agent, exerts stable application value across disease spectra including candidiasis and cryptococcal infections by inhibiting ergosterol biosynthesis. Its pharmacokinetic profile, characterized by high oral bioavailability, low protein binding, broad distribution across body fluids, and predominant renal excretion as unchanged drug, underpins its advantages in treatment strategies for CNS fungal infections and in step-down approaches for multiple systemic infections. In research, its core value lies in its role as a standard comparator, its utility for closed-loop validation of resistance mechanisms, and its capacity for PK/PD translational bridging. A mechanistically interpretable evidence chain is recommended, centered on standardized susceptibility systems, sterol profiling and efflux-pump readouts, and exposure–response models, to support transferable conclusions spanning efficacy improvement, resistance-risk control, and regimen optimization.

For more related articles, please see below:

[1] ADME/Tox: From Basics to Advanced – Metabolizing Enzymes, Transporters and Key Tool Compounds

[2] 1,2,4-Triazole Derivatives for Synthesis of Biologically Active Compounds